Technical Analysis – 12 August 2024

Shares closed higher above the 5dEMA. 5dEMA recently crossed the 20dEMA and 50dEMA.
MACD just turned positive, RSI is constructive.
Long – Entry 850 Target 890, Stop 830

Shares closed above the 50dEMA. The 5dEMA just crossed the 50dEMA and 20dEMA is about to cross the 50dEMA.
MACD is positive, RSI is constructive.
Long – Entry 25.20, Target 27.20, Stop 24.20

Eli Lilly And Co. (LLY)

2Q24 Revenue: $11.3B, +36.0% YoY, beat estimates by $1.33B
2Q24 Non-GAAP EPS: $3.92, beat estimates by $1.16
FY24 Guidance: Raise FY24 guidance. Expect revenue of $45.4bn to $46.6bn, compared with $42.4bn to $43.6bn previously and vs consensus of $42.95bn; Expect non-GAAP EPS to be between $16.10 to $16.60, compared to $13.50 to $14.00 previously, and vs consensus of $13.71; Expect non-GAAP expenses of $300mn to $400mn, compared to $400mn to $500mn previously. Expect incretin drug production in the second half of 2024 to be 50% higher YoY.
Comment: Eli Lilly and Co. reported robust results and raised its FY24 outlook, driven by a surge in sales of its blockbuster diabetes drug Mounjaro and weight loss injection Zepbound. The company gained better clarity on its production expansions and planned international launches of Mounjaro. The current market shows strong demand for incretin drugs like Zepbound and Mounjaro, surpassing supply. As a result, Eli Lilly is heavily investing in its supply chain to enhance manufacturing capacity. The Food and Drug Administration’s drug database recently confirmed that all doses of Zepbound and Mounjaro are now available in the U.S. after prolonged shortages, suggesting an improvement in the company’s supply challenges. Rising obesity rates are expected to sustain high demand for these weight loss drugs, benefiting Eli Lilly. 3Q24 recommended trading range: $800 to $1000. Positive Outlook.

礼来 (LLY)

24财年第二季营收：113亿美元，同比增幅36.0%，超预期13.3亿美元
24财年第二季Non-GAAP每股盈利：3.92美元，超预期0.16美元
24财年指引：提高24财年指引。预计营收为454亿美元至466亿美元，高于此前的424亿美元至436亿美元，也高于市场预期的429.5亿美元；预计Non-GAAP每股收益将在16.10美元至16.60美元之间，而此前为13.50美元至14.00美元，而市场预期为13.71美元；预计Non-GAAP费用为3亿至4亿美元，而之前为4亿至5亿美元。预计2024年下半年肠促胰岛素药物产量将同比增长50%。
短评：礼来公司公布了强劲的业绩，并上调了24财年的预期，这主要得益于其畅销的糖尿病药物Mounjaro和减肥注射剂Zepbound的销量激增。该公司更清楚地了解了其生产扩张和计划在国际上发布Mounjaro。目前市场对Zepbound和Mounjaro等促肠促素药物的需求强劲，供不应求。因此，礼来正在大力投资其供应链，以提高生产能力。美国食品和药物管理局的药物数据库最近证实，在长期短缺之后，Zepbound和Mounjaro的所有剂量现在都可以在美国买到，这表明该公司的供应挑战有所改善。预计不断上升的肥胖率将维持对这些减肥药的高需求，这将使礼来公司受益。24年第三季度建议交易区间：800至1000美元。积极前景。

Cheniere Energy Inc (LNG)

2Q24 Revenue: $3.25B, -20.7% YoY, miss estimates by $300M
2Q24 GAAP EPS: $3.84, beat estimates by $2.18
FY24 Guidance: Expect consolidated adjusted EBITDA between $5.7bn to $6.1bn, compared to $5.5bn to $6.0bn previously; Expect distributable cash flow of $3.1bn to $3.5bn, compared to $2.9bn to $3.4bn previously.
Comment: Cheniere Energy reported mixed results but remains optimistic about its outlook for the rest of the year, raising its FY24 adjusted EBITDA guidance. The company noted that the previous quarter saw a decline in net income and core earnings, primarily due to moderating international gas prices and a higher proportion of LNG sold under long-term contracts, which resulted in a lower total margin per MMBtu of LNG delivered. Cheniere expects the Asian market to continue driving strong LNG demand growth in the near term. Additionally, the company reported that its Corpus Christi Stage 3 export project in South Texas is progressing ahead of schedule and is expected to add 10 million metric tons per year to its existing production capacity of 15 million tons per year. 3Q24 recommended trading range: $175 to $195. Positive Outlook.

Cheniere Energy (LNG)

24财年第二季营收：32.5亿美元，同比跌幅20.7%，逊预期3亿美元
24财年第二季GAAP每股盈利：3.84美元，超预期2.18美元
24财年指引：预计经调整后的综合EBITDA将在57亿美元至61亿美元之间，而此前预计为55亿美元至60亿美元；预计可分配现金流为31亿至35亿美元，高于此前的29亿至34亿美元。
短评：Cheniere Energy公布的业绩好坏参半，但对今年剩余时间的前景仍持乐观态度，并上调了24财年调整后的EBITDA指引。该公司指出，上一季度净收入和核心收益下降，主要是由于国际天然气价格放缓以及根据长期合同销售的液化天然气比例上升，导致每百万英热单位液化天然气交付的总利润率下降。Cheniere预计亚洲市场将在短期内继续推动液化天然气需求的强劲增长。此外，该公司报告称，其位于德克萨斯州南部的Corpus Christi第三阶段出口项目正在提前进行，预计将在现有年产1500万吨的基础上每年增加1000万吨。24年第三季度建议交易区间：175至195美元。积极前景。